Exchange: NASDAQ·Updated 07:57 PM EDT

AZN News

News
all
press releases
FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug
AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.
Zacks
More News
Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?
AZN's pipeline setbacks weigh on its stock, but a deep late-stage pipeline and 20+ expected readouts offer key catalysts.
Zacks
Is It Worth Investing in Astrazeneca (AZN) Based on Wall Street's Bullish Views?
The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Zacks
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
Large-cap healthcare outperformed this week: XLV gained 1.4% through Tuesday, while XBI fell 1.4% and IBB declined 0.5%.
Stocktwits
CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot
Cellectis received a downgrade after pivoting to cardiovascular diseases therapy from a type of cancer therapy
Stocktwits
New Strong Sell Stocks for September 15th
APTV, AZN and OZK have been added to the Zacks Rank #5 (Strong Sell) List on September 15th, 2026.
Zacks
Why the Market Dipped But Astrazeneca (AZN) Gained Today
In the latest trading session, Astrazeneca (AZN) closed at $163.78, marking a +2.25% move from the previous day.
Zacks
AZN's Etcamah Fails Late-Stage Study for First-line Breast Cancer
AstraZeneca's Etcamah fails to improve PFS significantly in a phase III first-line breast cancer study, while its approved use remains unaffected.
Zacks
Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?
PFE faces COVID revenue declines and a patent cliff, but new products, acquisitions and a strong pipeline could fuel growth from 2029.
Zacks
Futures Slide As Tech Tumbles On Fears Of AI Slowdown, Oil Jumps
Futures Slide As Tech Tumbles On Fears Of AI Slowdown, Oil Jumps US futures are sliding, dragged by fears of a possible AI development slowdown as well as higher oil prices (Brent > 108), though bond yields are not reacting yet (10Y yield still under 5%). As of 8:00am ET, S&P futures...
Zero Hedge

Advertisement|Remove ads.